For informational purposes only — not investment advice

← Back to signals

FRNM

Freenome, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
8.1d↑+36.3%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Neutral

Freenome reported strong Q3 2026 results with $1.10 EPS driven by FDA approval of SimpleScreen CRC and a collaboration agreement (likely Abbott), plus promising lung cancer screening data with FDA Breakthrough Designation. However, Q4 revenue guidance of only $2–4M signals minimal near-term commercialization, and the stock has declined significantly below its 200-day moving average despite fundamental progress, suggesting market skepticism about execution or competitive positioning.

Red flags

  • •Minimal Q4 2026 revenue guidance ($2–4M) despite recent FDA approvals and partnerships, indicating slow commercial ramp
  • •No meaningful testing revenue or royalties expected in Q4, raising questions about market adoption and revenue timing
  • •Stock trading at 52-week lows despite positive Q3 earnings and product milestones, suggesting investor doubt about valuation or execution risk
  • •Heavy reliance on future milestone payments ($70M contingent on Abbott transfer expected H1 2028) with significant execution risk
  • •Major shareholder Highbridge Capital Management exited position entirely (8.1% to 0%), signaling insider lack of confidence

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Point72SC 13G/A—2.5%
+1.6% vs SPY
-1.6% abs
2026-11-16↗